Affinity Asset Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

Affinity Asset Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-44,348	Closed	-$296K	–	84
2023 Q3	$296K	Sell	44,348 -105,652	-70%	-$784K	0.08%	77
2023 Q2	$1.26M	Buy	+150,000	New	+$1.48M	0.44%	45
2022 Q1	–	Sell	-100,759	Closed	-$403K	–	60
2021 Q4	$403K	Sell	100,759 -97,000	-49%	-$740K	0.15%	52
2021 Q3	$1.74M	Sell	197,759 -2,241	-1%	-$20.6K	0.44%	45
2021 Q2	$2.27M	Sell	200,000 -100,000	-33%	-$1.2M	0.81%	30
2021 Q1	$3.56M	Buy	300,000 +200,000	+200%	+$2.3M	1.21%	21
2020 Q4	$686K	Buy	+100,000	New	+$702K	0.36%	52

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Affinity Asset Advisors's ALDX Position: Q4 2023 in Review

Affinity Asset Advisors sold out of Aldeyra Therapeutics (ALDX) in Q4 2023, closing a stake of 44,348 shares — an estimated $296K sold.

Affinity Asset Advisors first reported a position in ALDX in Q4 2020 and held it in 7 quarters. The position peaked at $3.56M in Q1 2021. 105 funds tracked by Wall St. Rank hold ALDX as of Q4 2023.

Affinity Asset Advisors reported no remaining Aldeyra Therapeutics position as of Q4 2023 after selling out during the quarter.
Affinity Asset Advisors sold 44,348 Aldeyra Therapeutics shares in Q4 2023, an estimated $296K.
Affinity Asset Advisors first reported a position in Aldeyra Therapeutics in Q4 2020 and held it in 7 quarters.
Affinity Asset Advisors's Aldeyra Therapeutics position peaked at $3.56M in Q1 2021.
105 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2023.

Based on Affinity Asset Advisors's 13F filing for Q4 2023, filed 13 Feb 2024.